NEW YORK, Oct. 29 /PRNewswire/ -- See video from Roche Pharmaceuticals at:
Roche announced on October 29 that the European Commission has approved the use of MabThera (rituximab) as a maintenance treatment for people suffering from follicular lymphoma who have responded to initial induction therapy. The approval of MabThera maintenance expands effective treatment options for people with this common type of incurable blood cancer, doubling the likelihood of them living longer without their disease worsening. Maintenance treatment is an important approach to blood cancer management as it reduces the risk of relapse and the use of repeated chemotherapy, ultimately improving the lives of follicular lymphoma patients. Available video includes expert's opinion on MabThera.
thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE and ZDF.
Registered journalists can access video, audio, text, graphics and photos at http://www.thenewsmarket.com.
If you are not already registered, please take a moment to sign up - registration is quick and free: http://www.thenewsmarket.com/registration
Story Id: 20278
|SOURCE thenewsmarket.com; Roche Pharmaceuticals|
Copyright©2010 PR Newswire.
All rights reserved